Theft prompts Novo Nordisk to increase security across its supply chain
Novo Nordisk, which is currently experiencing high demand for the company’s key products Ozempic for diabetes and Wegovy for obesity, has recently reported increasing problems with illegal sales of the company’s medicines.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.